metformin has been researched along with Delayed Effects, Prenatal Exposure in 55 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " While metformin has a mild androgen-lowering effect in non-pregnant women with PCOS, its effects on maternal androgen levels in pregnancy are less well understood." | 9.34 | Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus. ( Abbott, D; Andræ, F; Odsæter, IH; Salvesen, Ø; Schmedes, AV; Stridsklev, S; Vanky, E, 2020) |
| "Metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age." | 9.27 | Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. ( Carlsen, SM; Hanem, LGE; Júlíusson, PB; Roelants, M; Salvesen, Ø; Stridsklev, S; Vanky, E; Ødegård, R, 2018) |
| "Women randomized to metformin were heavier in the first trimester, gained less weight in pregnancy, and lost less weight in the first year postpartum compared with women randomized to placebo." | 9.16 | Metformin's effect on first-year weight gain: a follow-up study. ( Carlsen, SM; Martinussen, MP; Vanky, E, 2012) |
| " Metformin is taken by many patients before pregnancy due to both previously diagnosed type 2 diabetes and in the treatment of prediabetes, obesity and polycystic ovary syndrome (PCOS) as part of therapy for insulin resistance." | 9.05 | Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży]. ( Cichocka, E; Gumprecht, J; Kędzierski, L; Krupej-Kędzierska, J; Okopień, B, 2020) |
| "Our review found that metformin had no short-term adverse effects on pregnancy, potential benefits in the neonatal period, but limited long-term follow-up information." | 8.95 | Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. ( Aitken, E; Butalia, S; Donovan, L; Gutierrez, L; Lodha, A; Zakariasen, A, 2017) |
| "Metformin has no effect on the abortion risk in PCOS patients when administered before pregnancy." | 8.85 | Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Exposure to metformin in the first trimester of pregnancy." | 8.83 | Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "PCOS in women without metformin use during pregnancy was associated with higher risks of preeclampsia (OR = 1." | 8.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Gestational metformin attenuated the adiposity in obese dams and increased the gestation length without correcting the offspring in utero growth restriction and catch-up growth caused by maternal obesity." | 8.02 | Maternal Metformin Intervention during Obese Glucose-Intolerant Pregnancy Affects Adiposity in Young Adult Mouse Offspring in a Sex-Specific Manner. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Ozanne, SE; Schoonejans, JM, 2021) |
| " This study examined the effect of metformin on VPA-induced autism spectrum disorders in rats." | 7.96 | Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system. ( Adeyemi, OO; Balogun, AO; Ishola, IO, 2020) |
| "Metformin is an oral insulin-sensitizing anti-diabetic drug." | 6.50 | [Metformin in pregnancy]. ( Bijok, J; Bińkowska, M; Jakiel, G, 2014) |
| "Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 5.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
| "Metformin has been used for the treatment of some metabolic diseases during gestation and the beneficial effects of metformin to the vascular system have been described in diabetic and obese animal models." | 5.46 | Metformin Exposure During Pregnancy and Lactation Did Not Cause Vascular Reactivity Alteration in Adult Male Offsprings. ( Ceravolo, GS; Forcato, S; Gerardin, DCC; Loiola, GH; Novi, DRBS; Vidigal, CB, 2017) |
| " While metformin has a mild androgen-lowering effect in non-pregnant women with PCOS, its effects on maternal androgen levels in pregnancy are less well understood." | 5.34 | Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus. ( Abbott, D; Andræ, F; Odsæter, IH; Salvesen, Ø; Schmedes, AV; Stridsklev, S; Vanky, E, 2020) |
| "The addition of metformin to dietary and lifestyle advice in pregnancy for overweight and obese women has no clinically relevant effect on ultrasound measures of fetal biometry or adiposity." | 5.34 | Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial. ( Deussen, AR; Dodd, JM; Louise, J; Poprzeczny, AJ, 2020) |
| "Metformin is increasingly used to treat gestational diabetes and type 2 diabetes in pregnancy, and in attempts to improve pregnancy outcomes in polycystic ovary syndrome and obesity." | 5.30 | Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. ( Carlsen, SM; Hanem, LGE; Juliusson, PB; Nossum, MCF; Salvesen, Ø; Vaage, MØ; Vanky, E; Ødegård, R, 2019) |
| "Metformin is used in an attempt to reduce pregnancy complications associated with polycystic ovary syndrome (PCOS)." | 5.27 | Fetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS. ( Eggebø, T; Engen Hanem, LG; Hjorth-Hansen, A; Salvesen, KÅ; Salvesen, Ø; Vanky, E; Ødegård, R, 2018) |
| "Metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age." | 5.27 | Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. ( Carlsen, SM; Hanem, LGE; Júlíusson, PB; Roelants, M; Salvesen, Ø; Stridsklev, S; Vanky, E; Ødegård, R, 2018) |
| "Women randomized to metformin were heavier in the first trimester, gained less weight in pregnancy, and lost less weight in the first year postpartum compared with women randomized to placebo." | 5.16 | Metformin's effect on first-year weight gain: a follow-up study. ( Carlsen, SM; Martinussen, MP; Vanky, E, 2012) |
| " Metformin is taken by many patients before pregnancy due to both previously diagnosed type 2 diabetes and in the treatment of prediabetes, obesity and polycystic ovary syndrome (PCOS) as part of therapy for insulin resistance." | 5.05 | Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży]. ( Cichocka, E; Gumprecht, J; Kędzierski, L; Krupej-Kędzierska, J; Okopień, B, 2020) |
| "Oral antidiabetic medication of metformin is increasingly used in pregnant women with gestational diabetes mellitus (GDM), polycystic ovary syndrome (PCOS) and obesity." | 5.01 | Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis. ( Xie, Q; Xu, Q, 2019) |
| "Metformin use during pregnancy is controversial and there is disparity in the acceptance of metformin treatment in women with gestational diabetes mellitus (GDM) in Australia." | 4.95 | The emerging role of metformin in gestational diabetes mellitus. ( Cohen, N; Gray, SG; Little, PJ; McGuire, TM, 2017) |
| "Our review found that metformin had no short-term adverse effects on pregnancy, potential benefits in the neonatal period, but limited long-term follow-up information." | 4.95 | Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. ( Aitken, E; Butalia, S; Donovan, L; Gutierrez, L; Lodha, A; Zakariasen, A, 2017) |
| " Metformin is widely used in fertility treatment of women with PCOS, due to a suggested positive effect of continued metformin treatment beyond the first trimester on pregnancy complications." | 4.91 | [Metformin and the obstetric patient]. ( Aaboe, K; Bülow, NS; Galsgaard, J; Lauenborg, J; Mathiesen, ER; Odgaard, HS; Pedersen, KD, 2015) |
| "Metformin has no effect on the abortion risk in PCOS patients when administered before pregnancy." | 4.85 | Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Exposure to metformin in the first trimester of pregnancy." | 4.83 | Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "Elevated RIF1 in oocytes caused by maternal obesity may mediate abnormal embryonic epigenetic remodeling and increase metabolic risk in offspring by regulating histone modifications on MuERV-L, which can be partially rescued by metformin treatment." | 4.12 | Elevated RIF1 participates in the epigenetic abnormalities of zygotes by regulating histone modifications on MuERV-L in obese mice. ( Huang, J; Li, Z; Ru, G; Sun, J; Sun, L, 2022) |
| "PCOS in women without metformin use during pregnancy was associated with higher risks of preeclampsia (OR = 1." | 4.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Gestational metformin attenuated the adiposity in obese dams and increased the gestation length without correcting the offspring in utero growth restriction and catch-up growth caused by maternal obesity." | 4.02 | Maternal Metformin Intervention during Obese Glucose-Intolerant Pregnancy Affects Adiposity in Young Adult Mouse Offspring in a Sex-Specific Manner. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Fernandez-Twinn, DS; Ozanne, SE; Schoonejans, JM, 2021) |
| " The mothers of the cases/controls and their diagnoses of diabetes (DM) before/during pregnancy as well as their insulin/metformin prescriptions during pregnancy were identified." | 3.96 | Maternal diabetes and risk of childhood cancer in the offspring. ( Hirvonen, E; Leinonen, MK; Madanat-Harjuoja, LM; Pitkäniemi, J; Seppälä, LK; Vettenranta, K, 2020) |
| " This study examined the effect of metformin on VPA-induced autism spectrum disorders in rats." | 3.96 | Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system. ( Adeyemi, OO; Balogun, AO; Ishola, IO, 2020) |
| "The biguanide metformin (MET) has been used during pregnancy for treatment of polycystic ovary syndrome and gestational diabetes." | 3.88 | Intrauterine exposure to metformin: Evaluation of endothelial and perivascular adipose tissue function in abdominal aorta of adult offspring. ( Akamine, EH; Ceravolo, GS; da Silva, MDV; de Andrade, FG; Gerardin, DCC; Montagnini, BG; Moura, KF; Novi, DRBS; Picinin, R; Silva, RNOD; Vidigal, CB, 2018) |
| " Using metformin during pregnancy and nursing to improve the metabolic status of obese mothers could prevent the sequence of events that lead to an increase in postnatal serum estradiol levels in female offspring and, hence, reproductive dysfunction." | 3.88 | Prenatal metformin treatment improves ovarian function in offspring of obese rats. ( Álvarez, D; Ceballo, K; Cruz, G; Fernandois, D; Maliqueo, M; Martinez-Pinto, J; Olguín, S; Sotomayor-Zárate, R, 2018) |
| "Studies in rodents suggest that metformin treatment during pregnancy may have harmful effects on testicular development in offspring." | 3.83 | Metformin Treatment Does Not Affect Testicular Size in Offspring Born to Mothers with Gestational Diabetes. ( Rönnemaa, T; Sadov, S; Tertti, K; Toppari, J; Virtanen, HE, 2016) |
| "The antidiabetic drug metformin is currently used prior and during pregnancy for polycystic ovary syndrome, as well as during gestational diabetes mellitus." | 3.79 | Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood. ( Ailanen, L; Ilyasizadeh, J; Jäppinen, NT; Koulu, M; Laurila, K; Penttinen, AM; Pesonen, U; Salomäki, H; Vähätalo, LH, 2013) |
| "To evaluate the ovarian function during early infancy in daughters of women with polycystic ovary syndrome (PCOS) treated with metformin throughout pregnancy (PCOSd+M), as a means to reduce androgen and insulin levels, compared with daughters of nontreated PCOS women (PCOSd-M) and daughters of women who belong to a healthy comparison group (HCd)." | 3.78 | Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. ( Crisosto, N; Echiburú, B; Ladrón de Guevara, A; Maliqueo, M; Pérez, V; Preisler, J; Sánchez, F; Sir-Petermann, T, 2012) |
| "In women with gestational diabetes mellitus, who were randomized to metformin or insulin treatment, pregnancy outcomes were similar (Metformin in Gestational diabetes [MiG] trial)." | 3.77 | Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. ( Battin, M; Hague, WM; Obolonkin, V; Rowan, JA; Rush, EC; Wouldes, T, 2011) |
| "Offspring born following maternal gestational diabetes are at risk of excessive childhood weight gain and Type 2 diabetes in childhood, which in turn is associated with an increased rate of hypertension." | 2.80 | Blood pressure measurement at two years in offspring of women randomized to a trial of metformin for GDM: follow up data from the MiG trial. ( Battin, MR; Coat, S; Hague, W; Obolonkin, V; Rowan, J; Rush, E, 2015) |
| "Further studies are needed to assess treatment in pregnancy, perinatal outcomes, and particularly long-term metabolic profiles in mothers and offspring." | 2.61 | The Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy. ( Blair, RA; Palermo, NE; Rosenberg, EA, 2019) |
| "Metformin is an oral insulin-sensitizing anti-diabetic drug." | 2.50 | [Metformin in pregnancy]. ( Bijok, J; Bińkowska, M; Jakiel, G, 2014) |
| "Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 1.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
| "The aim of this study is to investigate the effects of metformin treatment at different dosage levels on the ovaries and uteruses of rat offspring in the course of the intrauterine period." | 1.62 | The effects of metformin treatment on the ovaries and uterus of offspring. ( Avcı, B; Ayas, B; Kırmızıkan, S; Kocaman, A, 2021) |
| "Metformin is a drug used for the treatment of type 2 diabetes and disorders associated with insulin resistance." | 1.62 | ( Acloque, H; Bertoldo, MJ; Chevaleyre, C; Dupont, J; Faure, MC; Fournier, I; Froment, P; Guerquin, MJ; Khoueiry, R; Quanico, J; Ramé, C; Salzet, M, 2021) |
| "Metformin is an emerging option for treating gestational diabetes (GDM)." | 1.51 | Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes. ( Boggess, K; Engel, SM; Funk, MJ; Howe, AS; Landi, SN; Radke, S; Stürmer, T, 2019) |
| "Metformin (MET) is a widely-used drug for the treatment of type 2 diabetes mellitus and gestational diabetes." | 1.51 | Reproductive evaluations in female rat offspring exposed to metformin during intrauterine and intrauterine/lactational periods. ( Ceccatto Gerardin, DC; Ceravolo, GS; da Silva Novi, DRB; de Góes, MLM; Forcato, S; Inhasz Kiss, AC; Montagnini, BG, 2019) |
| "Hippocampus-based learning and memory deficits are key symptoms of FASD." | 1.48 | Hippocampus-dependent memory and allele-specific gene expression in adult offspring of alcohol-consuming dams after neonatal treatment with thyroxin or metformin. ( Ferreira, A; Lim, PH; Redei, EE; Tunc-Ozcan, E; Wert, SL, 2018) |
| "Metformin has been used for the treatment of some metabolic diseases during gestation and the beneficial effects of metformin to the vascular system have been described in diabetic and obese animal models." | 1.46 | Metformin Exposure During Pregnancy and Lactation Did Not Cause Vascular Reactivity Alteration in Adult Male Offsprings. ( Ceravolo, GS; Forcato, S; Gerardin, DCC; Loiola, GH; Novi, DRBS; Vidigal, CB, 2017) |
| "Metformin was administered during gestation from E0." | 1.40 | Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring. ( Ailanen, L; Eerola, K; Heinäniemi, M; Koulu, M; Pesonen, U; Ruohonen, ST; Salomäki, H; Vähätalo, LH, 2014) |
| "Metformin is a drug used in the treatment of diabetes and of some disorders related to insulin resistance, such as polycystic ovary syndrome." | 1.38 | Metformin exposure affects human and mouse fetal testicular cells. ( Dupont, J; Froment, P; Frydman, N; Frydman, R; Guibert, E; Habert, R; Lecureuil, C; Moison, D; Pozzi, S; Rouiller-Fabre, V; Tartarin, P, 2012) |
| "Metformin treatment of PNA mice restored firing activity and LH to control levels." | 1.37 | Prenatal androgenization of female mice programs an increase in firing activity of gonadotropin-releasing hormone (GnRH) neurons that is reversed by metformin treatment in adulthood. ( Moenter, SM; Roland, AV, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (7.27) | 29.6817 |
| 2010's | 35 (63.64) | 24.3611 |
| 2020's | 16 (29.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, J | 2 |
| Song, L | 2 |
| Wang, R | 2 |
| Hu, S | 2 |
| Yang, Z | 1 |
| Zhang, Z | 1 |
| Sun, B | 2 |
| Cui, W | 1 |
| Faure, MC | 1 |
| Khoueiry, R | 1 |
| Quanico, J | 1 |
| Acloque, H | 1 |
| Guerquin, MJ | 1 |
| Bertoldo, MJ | 1 |
| Chevaleyre, C | 1 |
| Ramé, C | 1 |
| Fournier, I | 1 |
| Salzet, M | 1 |
| Dupont, J | 2 |
| Froment, P | 2 |
| Huang, J | 1 |
| Ru, G | 1 |
| Sun, J | 1 |
| Sun, L | 1 |
| Li, Z | 1 |
| Fornes, R | 1 |
| Simin, J | 1 |
| Nguyen, MH | 1 |
| Cruz, G | 2 |
| Crisosto, N | 2 |
| van der Schaaf, M | 1 |
| Engstrand, L | 1 |
| Brusselaers, N | 1 |
| Elnahas, EM | 1 |
| Abuelezz, SA | 1 |
| Mohamad, MI | 1 |
| Nabil, MM | 1 |
| Abdelraouf, SM | 1 |
| Bahaa, N | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 1 |
| Li, H | 1 |
| Schoonejans, JM | 2 |
| Blackmore, HL | 2 |
| Ashmore, TJ | 2 |
| Pantaleão, LC | 1 |
| Pellegrini Pisani, L | 1 |
| Dearden, L | 1 |
| Tadross, JA | 1 |
| Aiken, CE | 2 |
| Fernandez-Twinn, DS | 2 |
| Ozanne, SE | 2 |
| Seppälä, LK | 1 |
| Vettenranta, K | 1 |
| Pitkäniemi, J | 1 |
| Hirvonen, E | 1 |
| Leinonen, MK | 1 |
| Madanat-Harjuoja, LM | 1 |
| Blair, RA | 1 |
| Rosenberg, EA | 1 |
| Palermo, NE | 1 |
| Panagiotopoulou, O | 1 |
| Syngelaki, A | 1 |
| Georgiopoulos, G | 1 |
| Simpson, J | 1 |
| Akolekar, R | 1 |
| Shehata, H | 1 |
| Nicolaides, K | 1 |
| Charakida, M | 1 |
| Carlson, Z | 1 |
| Hafner, H | 2 |
| Mulcahy, M | 1 |
| Bullock, K | 1 |
| Zhu, A | 1 |
| Bridges, D | 1 |
| Bernal-Mizrachi, E | 2 |
| Gregg, B | 1 |
| Krupej-Kędzierska, J | 1 |
| Cichocka, E | 1 |
| Kędzierski, L | 1 |
| Okopień, B | 1 |
| Gumprecht, J | 1 |
| Ishola, IO | 1 |
| Balogun, AO | 1 |
| Adeyemi, OO | 1 |
| Andræ, F | 1 |
| Abbott, D | 1 |
| Stridsklev, S | 2 |
| Schmedes, AV | 1 |
| Odsæter, IH | 1 |
| Vanky, E | 5 |
| Salvesen, Ø | 4 |
| Poprzeczny, AJ | 1 |
| Louise, J | 1 |
| Deussen, AR | 1 |
| Dodd, JM | 1 |
| Ayas, B | 1 |
| Kırmızıkan, S | 1 |
| Kocaman, A | 1 |
| Avcı, B | 1 |
| Tunc-Ozcan, E | 1 |
| Wert, SL | 1 |
| Lim, PH | 1 |
| Ferreira, A | 1 |
| Redei, EE | 1 |
| Novi, DRBS | 2 |
| Forcato, S | 3 |
| Vidigal, CB | 2 |
| Loiola, GH | 1 |
| Gerardin, DCC | 3 |
| Ceravolo, GS | 4 |
| Novi, DRBDS | 1 |
| Costa, NO | 1 |
| Borges, LI | 1 |
| Góes, MLM | 1 |
| Hjorth-Hansen, A | 1 |
| Engen Hanem, LG | 1 |
| Eggebø, T | 1 |
| Salvesen, KÅ | 1 |
| Ødegård, R | 3 |
| Deng, J | 1 |
| Mueller, M | 1 |
| Geng, T | 1 |
| Shen, Y | 1 |
| Liu, Y | 1 |
| Hou, P | 1 |
| Mamillapalli, R | 1 |
| Taylor, HS | 1 |
| Paidas, M | 1 |
| Huang, Y | 1 |
| Hanem, LGE | 2 |
| Júlíusson, PB | 2 |
| Roelants, M | 1 |
| Carlsen, SM | 3 |
| Tain, YL | 1 |
| Wu, KLH | 1 |
| Lee, WC | 1 |
| Leu, S | 1 |
| Chan, JYH | 1 |
| Gregg, BE | 1 |
| Botezatu, N | 1 |
| Brill, JD | 1 |
| Vadrevu, S | 1 |
| Satin, LS | 1 |
| Alejandro, EU | 1 |
| Moura, KF | 1 |
| Picinin, R | 1 |
| Montagnini, BG | 2 |
| Silva, RNOD | 1 |
| da Silva, MDV | 1 |
| de Andrade, FG | 1 |
| Akamine, EH | 1 |
| Vora, NL | 1 |
| Grace, MR | 1 |
| Smeester, L | 1 |
| Dotters-Katz, SK | 1 |
| Fry, RC | 1 |
| Bae-Jump, V | 1 |
| Boggess, K | 2 |
| Álvarez, D | 1 |
| Ceballo, K | 1 |
| Olguín, S | 1 |
| Martinez-Pinto, J | 1 |
| Maliqueo, M | 2 |
| Fernandois, D | 1 |
| Sotomayor-Zárate, R | 1 |
| Garbarino, VR | 1 |
| Santos, TA | 1 |
| Nelson, AR | 1 |
| Zhang, WQ | 1 |
| Smolik, CM | 1 |
| Javors, MA | 1 |
| Daws, LC | 1 |
| Gould, GG | 1 |
| Landi, SN | 1 |
| Radke, S | 1 |
| Engel, SM | 1 |
| Stürmer, T | 1 |
| Howe, AS | 1 |
| Funk, MJ | 1 |
| Nossum, MCF | 1 |
| Vaage, MØ | 1 |
| Abruzzese, GA | 1 |
| Heber, MF | 1 |
| Ferrer, MJ | 1 |
| Ferreira, SR | 1 |
| Silva, AF | 1 |
| Motta, AB | 1 |
| Xu, Q | 1 |
| Xie, Q | 1 |
| de Góes, MLM | 1 |
| da Silva Novi, DRB | 1 |
| Inhasz Kiss, AC | 1 |
| Ceccatto Gerardin, DC | 1 |
| Salomäki, H | 2 |
| Vähätalo, LH | 2 |
| Laurila, K | 1 |
| Jäppinen, NT | 1 |
| Penttinen, AM | 1 |
| Ailanen, L | 2 |
| Ilyasizadeh, J | 1 |
| Pesonen, U | 2 |
| Koulu, M | 2 |
| Bijok, J | 1 |
| Bińkowska, M | 1 |
| Jakiel, G | 1 |
| Fantus, IG | 1 |
| Heinäniemi, M | 1 |
| Eerola, K | 1 |
| Ruohonen, ST | 1 |
| Padmanabhan, V | 1 |
| Veiga-Lopez, A | 1 |
| Herkimer, C | 1 |
| Abi Salloum, B | 1 |
| Moeller, J | 1 |
| Beckett, E | 1 |
| Sreedharan, R | 1 |
| Battin, MR | 1 |
| Obolonkin, V | 2 |
| Rush, E | 1 |
| Hague, W | 1 |
| Coat, S | 1 |
| Rowan, J | 1 |
| Pedersen, KD | 1 |
| Bülow, NS | 1 |
| Aaboe, K | 1 |
| Galsgaard, J | 1 |
| Odgaard, HS | 1 |
| Mathiesen, ER | 1 |
| Lauenborg, J | 1 |
| Tertti, K | 1 |
| Toppari, J | 1 |
| Virtanen, HE | 1 |
| Sadov, S | 1 |
| Rönnemaa, T | 1 |
| Andrade, C | 1 |
| Butalia, S | 1 |
| Gutierrez, L | 1 |
| Lodha, A | 1 |
| Aitken, E | 1 |
| Zakariasen, A | 1 |
| Donovan, L | 1 |
| Gandica, R | 1 |
| Zeitler, P | 1 |
| Gray, SG | 1 |
| McGuire, TM | 1 |
| Cohen, N | 1 |
| Little, PJ | 1 |
| Palomba, S | 1 |
| Falbo, A | 1 |
| Orio, F | 1 |
| Zullo, F | 1 |
| Roland, AV | 1 |
| Moenter, SM | 1 |
| Rowan, JA | 2 |
| Rush, EC | 1 |
| Battin, M | 1 |
| Wouldes, T | 1 |
| Hague, WM | 1 |
| Echiburú, B | 1 |
| Pérez, V | 1 |
| Ladrón de Guevara, A | 1 |
| Preisler, J | 1 |
| Sánchez, F | 1 |
| Sir-Petermann, T | 1 |
| Tartarin, P | 1 |
| Moison, D | 1 |
| Guibert, E | 1 |
| Habert, R | 1 |
| Rouiller-Fabre, V | 1 |
| Frydman, N | 1 |
| Pozzi, S | 1 |
| Frydman, R | 1 |
| Lecureuil, C | 1 |
| Martinussen, MP | 1 |
| Cleasby, ME | 1 |
| Livingstone, DE | 1 |
| Nyirenda, MJ | 1 |
| Seckl, JR | 1 |
| Walker, BR | 1 |
| Gilbert, C | 1 |
| Valois, M | 1 |
| Koren, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)[NCT00159536] | Phase 3 | 257 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study[NCT03259919] | Phase 2 | 40 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
11 reviews available for metformin and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
The Use of Non-insulin Agents in Gestational Diabetes: Clinical Considerations in Tailoring Therapy.
Topics: Acarbose; Diabetes, Gestational; Female; Glyburide; Healthy Lifestyle; Humans; Hypoglycemic Agents; | 2019 |
Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży].
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pr | 2020 |
Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis.
Topics: Child; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Long Term Adve | 2019 |
[Metformin in pregnancy].
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycysti | 2014 |
[Metformin and the obstetric patient].
Topics: Breast Feeding; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ov | 2015 |
Major malformation risk, pregnancy outcomes, and neurodevelopmental outcomes associated with metformin use during pregnancy.
Topics: Abnormalities, Drug-Induced; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Infan | 2016 |
Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fetal Development; Humans; Hypoglyc | 2017 |
Update on Youth-Onset Type 2 Diabetes: Lessons Learned from the Treatment Options for Type 2 Diabetes in Adolescents and Youth Clinical Trial.
Topics: Adolescent; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; | 2016 |
The emerging role of metformin in gestational diabetes mellitus.
Topics: Australia; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Pregnancy | 2017 |
Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Abortion, Spontaneous; Adult; Algorithms; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation | 2009 |
Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Canada; Comorbidity; Female; Humans; Hypoglycemic Agents; Incidence; Me | 2006 |
9 trials available for metformin and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring.
Topics: Adiponectin; Adult; Arterial Pressure; Blood Pressure; Body Composition; Child, Preschool; Cholester | 2020 |
Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus.
Topics: Adult; Androgens; Body Mass Index; Female; Fetal Blood; Fetus; Humans; Hyperandrogenism; Male; Metfo | 2020 |
Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial.
Topics: Adiposity; Adult; Body Mass Index; Diet; Exercise; Female; Fetal Development; Fetus; Gestational Age | 2020 |
Fetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS.
Topics: Adult; Birth Weight; Double-Blind Method; Female; Fetal Development; Humans; Infant, Newborn; Metfor | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial.
Topics: Adult; Body Mass Index; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hypoglycemic Age | 2019 |
Blood pressure measurement at two years in offspring of women randomized to a trial of metformin for GDM: follow up data from the MiG trial.
Topics: Blood Pressure; Body Fat Distribution; Child, Preschool; Diabetes, Gestational; Female; Follow-Up St | 2015 |
Metformin's effect on first-year weight gain: a follow-up study.
Topics: Adult; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infant; Infant, | 2012 |
A trial in progress: gestational diabetes. Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial).
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Morbidity; Pr | 2007 |
35 other studies available for metformin and Delayed Effects, Prenatal Exposure
| Article | Year |
|---|---|
Maternal Metformin Treatment during Gestation and Lactation Improves Skeletal Muscle Development in Offspring of Rat Dams Fed High-Fat Diet.
Topics: Animals; Biomarkers; Body Weight; Diet, High-Fat; Female; Gene Expression Regulation; Gestational Ag | 2021 |
Topics: Animals; DNA Damage; DNA Methylation; DNA-Binding Proteins; Female; Hypoglycemic Agents; Infertility | 2021 |
Elevated RIF1 participates in the epigenetic abnormalities of zygotes by regulating histone modifications on MuERV-L in obese mice.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Disease Susceptibility; Embryonic Development; Epig | 2022 |
Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study.
Topics: Adult; Child; Child, Preschool; Cohort Studies; Diabetes, Gestational; Female; Humans; Infant, Newbo | 2022 |
Novel role of peroxisome proliferator activated receptor-α in valproic acid rat model of autism: Mechanistic study of risperidone and metformin monotherapy versus combination.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
Maternal Treatment with Metformin Persistently Ameliorates High-Fat Diet-Induced Metabolic Symptoms and Modulates Gut Microbiota in Rat Offspring.
Topics: Animals; Diet, High-Fat; Female; Gastrointestinal Microbiome; Humans; Inflammation; Male; Maternal N | 2022 |
Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring.
Topics: Adult; Animals; Body Composition; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diet, Hig | 2022 |
Maternal diabetes and risk of childhood cancer in the offspring.
Topics: Adolescent; Case-Control Studies; Child; Child, Preschool; Diabetes Mellitus; Diabetes, Gestational; | 2020 |
Lactational metformin exposure programs offspring white adipose tissue glucose homeostasis and resilience to metabolic stress in a sex-dependent manner.
Topics: Adipose Tissue, White; Animals; Cell Proliferation; Female; Glucose; Homeostasis; Hypoglycemic Agent | 2020 |
Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system.
Topics: Animals; Anticonvulsants; Antioxidants; Autism Spectrum Disorder; Disease Models, Animal; Female; Hy | 2020 |
The effects of metformin treatment on the ovaries and uterus of offspring.
Topics: Animals; Endometrium; Estradiol; Female; Hypoglycemic Agents; Metformin; Oocytes; Organ Size; Ovaria | 2021 |
Maternal Metformin Intervention during Obese Glucose-Intolerant Pregnancy Affects Adiposity in Young Adult Mouse Offspring in a Sex-Specific Manner.
Topics: Adiposity; Animals; Animals, Newborn; Diabetes, Gestational; Female; Male; Metformin; Mice; Mice, In | 2021 |
Hippocampus-dependent memory and allele-specific gene expression in adult offspring of alcohol-consuming dams after neonatal treatment with thyroxin or metformin.
Topics: Alcohol Drinking; Alleles; Animals; Ethanol; Fear; Female; Fetal Alcohol Spectrum Disorders; Hippoca | 2018 |
Metformin Exposure During Pregnancy and Lactation Did Not Cause Vascular Reactivity Alteration in Adult Male Offsprings.
Topics: Age Factors; Animals; Animals, Newborn; Aorta, Thoracic; Dose-Response Relationship, Drug; Female; H | 2017 |
In utero and lactational exposure to metformin induces reproductive alterations in male rat offspring.
Topics: Animals; Body Weight; Female; Fertility; Genitalia, Male; Hypoglycemic Agents; Lactation; Male; Mate | 2017 |
H19 lncRNA alters methylation and expression of Hnf4α in the liver of metformin-exposed fetuses.
Topics: Adenosylhomocysteinase; Animals; Base Sequence; Cell Line, Tumor; Female; Fetus; Gene Expression Pro | 2017 |
Prenatal Metformin Therapy Attenuates Hypertension of Developmental Origin in Male Adult Offspring Exposed to Maternal High-Fructose and Post-Weaning High-Fat Diets.
Topics: Animals; Diet, High-Fat; Female; High Fructose Corn Syrup; Hypertension; Hypoglycemic Agents; Male; | 2018 |
Gestational exposure to metformin programs improved glucose tolerance and insulin secretion in adult male mouse offspring.
Topics: Age Factors; Animals; Disease Models, Animal; Female; Glucose; Glucose Tolerance Test; Insulin; Insu | 2018 |
Intrauterine exposure to metformin: Evaluation of endothelial and perivascular adipose tissue function in abdominal aorta of adult offspring.
Topics: Adipose Tissue; Animals; Aorta, Abdominal; Body Weight; Dose-Response Relationship, Drug; Endothelia | 2018 |
Targeted Multiplex Gene Expression Profiling to Measure High-Fat Diet and Metformin Effects on Fetal Gene Expression in a Mouse Model.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Female; Fetal Development; Gene Expression; Gene Ex | 2019 |
Prenatal metformin treatment improves ovarian function in offspring of obese rats.
Topics: Animals; Diet, High-Fat; Drug Evaluation, Preclinical; Female; Hypoglycemic Agents; Lactation; Metfo | 2018 |
Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice.
Topics: Animals; Behavior, Animal; Brain; Female; Hypoglycemic Agents; Male; Maternal-Fetal Exchange; Metfor | 2019 |
Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes.
Topics: Adult; Child Behavior; Child Development; Child, Preschool; Diabetes, Gestational; Female; Follow-Up | 2019 |
Effects of in utero androgen excess and metformin treatment on hepatic functions.
Topics: Animals; Female; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Liver Dis | 2019 |
Reproductive evaluations in female rat offspring exposed to metformin during intrauterine and intrauterine/lactational periods.
Topics: Animals; Behavior, Animal; Estradiol; Estrous Cycle; Female; Fertility; Hypoglycemic Agents; Lactati | 2019 |
Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood.
Topics: Animals; Body Weight; Diet, High-Fat; Eating; Female; Fetus; Gene Expression Regulation; Glucose Tol | 2013 |
Is metformin ready for prime time in pregnancy? Probably not yet.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Po | 2015 |
Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring.
Topics: Adipocytes; Adipokines; Adipose Tissue, White; Animals; Blood Glucose; Body Weight; Cell Size; Diet, | 2014 |
Developmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.
Topics: Androgen Antagonists; Androgens; Animals; Estrous Cycle; Female; Fetal Development; Flutamide; Hypog | 2015 |
Metformin Treatment Does Not Affect Testicular Size in Offspring Born to Mothers with Gestational Diabetes.
Topics: Adult; Child; Child, Preschool; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin; | 2016 |
Prenatal androgenization of female mice programs an increase in firing activity of gonadotropin-releasing hormone (GnRH) neurons that is reversed by metformin treatment in adulthood.
Topics: Animals; Dihydrotestosterone; Electrophysiology; Estrous Cycle; Female; Glucose Tolerance Test; Gona | 2011 |
Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age.
Topics: Absorptiometry, Photon; Anthropometry; Body Composition; Child, Preschool; Diabetes, Gestational; Fe | 2011 |
Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters.
Topics: Adult; Anti-Mullerian Hormone; Birth Weight; Diabetes, Gestational; Female; Fertility Agents, Female | 2012 |
Metformin exposure affects human and mouse fetal testicular cells.
Topics: Animals; Animals, Newborn; Cell Proliferation; Embryo, Mammalian; Female; Gene Expression Regulation | 2012 |
Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?
Topics: Animals; Appetite; Body Weight; Corticosterone; Dexamethasone; Female; Gene Expression; Glucocortico | 2003 |